The weight loss drug market is bracing itself for a transformative year in 2026, with significant changes anticipated for GLP ...

Novo Nordisk has had a difficult year: a tumbling stock price resulting in the biggest leadership shakeup in the company's ...

Novo Nordisk is lowering prices of its top-selling obesity drug Wegovy in China, the Danish drugmaker said on Monday, as it ...

Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China, according to ...

Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) scored a major win earlier this month after it secured the Food and ...

Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

The U.S. Food and Drug Administration's approval of an oral version of Novo Nordisk's weight-loss drug Wegovy could ...

Novo Nordisk has won the race to secure approval from the FDA for the first weight-loss drug to be administered orally ...

Relief rally underway in Novo Nordisk after a difficult year for the stock which saw it lose ground to arch-competitor Eli ...

The U.S. Food and Drug Administration has approved Novo Nordisk’s Wegovy® pill, making it the first and only oral GLP-1 ...

Novo Nordisk shares surged Tuesday after the company said it received FDA approval for an oral version of its injectable weight-loss drug Wegovy.